i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

i-LUMEN-SCIENTIFIC

More Like This

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

PR Newswire associated0

LUMA Vision Expands Clinical Use of VERAFEYE™ in Guiding AF Ablations and Completes Key 510k Submission.

MacuMira and Keeler announce strategic partnership to expand Dry AMD therapy

LUMA Vision Co-Founders, CEO Fionn Lahart (right) and Chief Technology Officer Christoph Hennersperger (left). (Photo: Business Wire)

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform